Gender Bias in Medical Research: Why Women’s Heart Health Is Overlooked

Medical research has historically relied on male participants to establish treatment protocols, leading to systemic disparities in how women are diagnosed and treated for critical health conditions, including cardiovascular diseases.

The reliance on male-centric data has created a gap in clinical understanding, where the male body is treated as the biological norm and the female body is viewed as atypical. This disparity persists across biomedical research, clinical care, and health policy, despite a growing recognition of how sex-specific disease mechanisms and treatment responses differ.

Historical Exclusion in Clinical Research

The underrepresentation of women in medical studies is rooted in long-standing practices. According to the Association of American Medical Colleges, women were rarely included in clinical trials before 1993.

This historical exclusion was driven by several factors, including policies intended to shield unborn children from potential drug exposure and overarching misogyny within the medical field. Research data collected from males were frequently generalized to females, assuming that biological differences would not significantly alter the outcome of treatments.

Even in preclinical research, bias remains prevalent. Some medical researchers avoid using female mice in studies due to the higher costs associated with housing both sexes and concerns that fluctuating hormones and reproductive systems in females might confound results.

Impact on Cardiovascular Care

The consequences of this research gap are particularly evident in the management of cardiovascular diseases (CVDs). Women are less likely to receive appropriate prevention and management for heart disease compared to men.

An analysis of 19 studies published on February 15, 2024, found that CVDs were less frequently reported among women. The findings indicated that women either exhibited milder symptoms than men or had symptoms that were overlooked or misinterpreted by clinicians.

Because treatment protocols are often based on male-centric data, there is often insufficient information to support precision care for women, who may experience heart disease differently than men.

Adverse Effects and Device Failures

The failure to study medications and medical interventions across a diverse sampling of women has led to measurable risks in patient safety. Women experience adverse effects from medications at twice the rate of men.

Beyond pharmaceuticals, medical devices have also shown higher failure rates in women due to inadequate testing and a failure to account for anatomical differences. A 2013 study highlighted this issue, finding that women with metal hip replacements were 29% more likely than men to experience implant failure.

The Path Toward Precision Care

While policy and social changes in the 1990s helped increase the inclusion of women in research, significant gaps remain. The lack of data on how women, particularly women of color, experience disease continues to contribute to health care disparities.

Biological sex influences physiological, metabolic, hormonal, and cellular differences that dictate how diseases present and how effective a pharmaceutical or device will be.

Current evidence suggests that overcoming these disparities requires a shift away from the male-as-norm model toward research that explicitly accounts for sex-specific mechanisms to ensure equitable health outcomes for all patients.